Drug Shortages: Inside the Broken Pharmaceutical Supply Chain

A recent Pharmaceutical Technology article explains that shortages often stem from a combination of manufacturing quality issues, limited production capacity, raw material dependence, regulatory hurdles, logistics disruptions, and sudden demand fluctuations. Rather than isolated incidents, these shortages reflect systemic weaknesses that require coordinated industry action.

• Patient access is at risk when essential medicines become unavailable or treatment is delayed.
• Manufacturers face increasing pressure to strengthen supplier diversification, improve forecasting, and invest in resilient production networks.
• Supply chain visibility has become a strategic priority, enabling companies to identify risks earlier and respond more effectively to disruptions.
• Collaboration across regulators, manufacturers, suppliers, and healthcare providers is critical to improving long-term supply resilience.

Drug shortages are no longer just an operational challenge—they have become a strategic business risk. Building resilient pharmaceutical supply chains requires more than increasing inventory; it demands diversified sourcing, digital visibility, proactive risk management, and closer collaboration across the entire value chain.

Organizations that invest in resilience today will be better positioned to ensure continuous patient access and navigate future disruptions.

Source: Pharmaceutical Technology – "Drug Shortages Explained: Inside the Broken Supply Chain"